AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Acting Secretary for Health Dr Libby Lee chairs the 20th meeting of the Cancer Coordinating Committee to discuss the response ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

Shares of Guardant Health Inc (NASDAQ:GH) climbed 3.7% as the company announced its Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the U.S. Food and Drug ...

Air pollution is the least recognised of the big five preventable causes of disease in the UK, and doctors should take it more seriously, England’s chief medical officer has said. Chris Whitty said ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

Engaging in leisure-time MVPA linked to improved survival for various cancer types including bladder, breast, colon.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.